NDAORALSYRUP
Approved
Jul 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MULTIFUGE is a piperazine citrate oral syrup approved in 1954 for the treatment of parasitic infections, primarily roundworms and pinworms. As an anthelmintic agent, it works by paralyzing parasites, enabling their expulsion from the gastrointestinal tract. This legacy product remains a cost-effective option in resource-limited settings and pediatric populations.
LOE Approaching
Legacy product nearing loss of exclusivity with minimal linked career opportunities and likely contracted team size focused on generic transition management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MULTIFUGE offers minimal career advancement opportunity with zero linked job positions currently active. Working on this product at LOE stage involves transition management, cost optimization, and regulatory maintenance rather than commercial or clinical growth.
Supply Chain ManagerRegulatory Affairs Specialist
Worked on MULTIFUGE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.